Havrix Junior

Havrix Junior is a prescription‑only hepatitis A vaccine that contains inactivated hepatitis A virus and the adjuvant algeldrate. It is supplied as an injectable solution for intramuscular administration. Marketed in the European Union, the product is classified under ATC code J07BC01 and is intended to provide active immunity against hepatitis A infection. The vaccine is used in pediatric immunization programs and national schedules through public health programs.

Havrix Junior is indicated for the prevention of hepatitis A infection in children and adolescents.

- Active immunization of individuals aged 1 year and older who have not been previously exposed to hepatitis A virus. - Inclusion in routine childhood vaccination schedules as recommended by national health authorities. - Protection of travelers to regions where hepatitis A is endemic when administered according to travel‑related vaccination guidelines. - Use in outbreak control settings to quickly establish herd immunity among susceptible pediatric populations. - Administration prior to exposure in household contacts of hepatitis A cases, when clinically appropriate.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache or mild fatigue. - Transient muscle or joint aches.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat, or hives. - Neurological events such as Guillain‑Barré syndrome, although causality is rare. - Persistent high fever lasting more than 48 hours. - Unexplained bleeding or bruising.

Before administering Havrix Junior, healthcare providers should consider several precautionary factors to ensure safe use.

- Confirm that the child has no known severe allergy to any vaccine component, including algeldrate. - Defer vaccination in individuals with a moderate or severe acute illness until recovery. - Evaluate the need for vaccination in immunocompromised patients on a case‑by‑case basis. - Review pregnancy status; the vaccine’s safety in pregnancy has not been established. - Observe the patient for at least 15 minutes after injection for immediate hypersensitivity reactions. - Document any previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Junior may interact with other medicines or vaccines; awareness of these interactions helps optimize immunization schedules.

Avoid: - Concurrent administration with live‑attenuated vaccines (e.g., measles‑mumps‑rubella) without appropriate interval, as immune interference may reduce efficacy. - Use in individuals receiving high‑dose immunoglobulin therapy within 2 weeks, which can neutralize the vaccine antigen.

Use with caution: - Simultaneous receipt of other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) is generally acceptable but monitor for increased local reactions. - Patients on immunosuppressive therapy may have a reduced antibody response; consider serologic testing after completion of the series. - Antipyretics (acetaminophen, ibuprofen) can be used to manage mild post‑vaccination symptoms, but routine prophylactic use may blunt the immune response.